NYSE:ANVS Annovis Bio Q1 2025 Earnings Results & Report $1.04 -0.11 (-9.13%) As of 09:50 AM Eastern This is a fair market value price provided by Massive. Learn more. Annovis Bio beat analyst earnings expectations in its Q1 2025 results, released May 13, 2025. The company reported EPS of -$0.32 versus the -$0.47 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 13, 2025TimeBefore Market OpensConference Call12:00 AM ET Annovis Bio EPS ResultsActual EPS-$0.32Consensus EPS -$0.47Beat/MissBeat by +$0.15One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersAnnovis Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAnnovis Bio's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Annovis Bio Q1 2025 Earnings FAQ Did Annovis Bio beat earnings estimates for Q1 2025? Annovis Bio (NYSE:ANVS) reported earnings of -$0.32 per share for Q1 2025, beating the consensus estimate of -$0.47. The report was announced on Tuesday, May 13, 2025. When is Annovis Bio's next earnings date? Annovis Bio's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Annovis Bio on the company's earnings history page. Annovis Bio Earnings HeadlinesAnnovis Collaborates With Weave Bio On AI Use In NDA Submission For ButanetapSeptember 23, 2026 | rttnews.comAnnovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s DiseaseSeptember 23, 2026 | markets.businessinsider.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's DiseaseSeptember 23, 2026 | globenewswire.comAnnovis Bio consensus price target lowered by 16.67% to $10.71September 15, 2026 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbbVie (ABBV)September 5, 2026 | theglobeandmail.comSee More Annovis Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email. Email Address About Annovis BioAnnovis Bio (NYSE:ANVS) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. The company’s research centers on treatments designed to address the underlying mechanisms that contribute to the accumulation of multiple neurotoxic proteins in the brain. Annovis’ lead drug candidate is buntanetap, formerly known as ANVS401. The orally administered small-molecule therapy is being developed to reduce the production of several neurotoxic proteins, including amyloid beta, tau and alpha-synuclein, which are associated with neurodegenerative disorders. The company has evaluated buntanetap in clinical studies involving patients with Alzheimer’s and Parkinson’s disease. Annovis Bio was founded in 2008 and is headquartered in Berwyn, Pennsylvania. The company’s operations are focused on research and clinical development, with its programs subject to ongoing evaluation for safety and effectiveness. Maria Maccecchini, Ph.D., the company’s founder, serves as president and chief executive officer.View Annovis Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
